IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Increased by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 471,533 shares of the medical research company's stock after buying an additional 33,455 shares during the period. IQVIA makes up about 1.8% of Douglass Winthrop Advisors LLC's holdings, making the stock its 24th biggest holding. Douglass Winthrop Advisors LLC owned approximately 0.26% of IQVIA worth $92,661,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter valued at about $33,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after buying an additional 87 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock worth $58,000 after buying an additional 191 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on IQV shares. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Stephens started coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price for the company. Truist Financial restated a "buy" rating and set a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Stock Performance

IQV traded down $5.04 during trading hours on Tuesday, hitting $181.07. The company's stock had a trading volume of 1,566,007 shares, compared to its average volume of 1,239,209. The company has a 50-day simple moving average of $194.58 and a 200 day simple moving average of $207.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $31.93 billion, a PE ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.54.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.